In our recent study, this method demonstrated efficacy in assessing HER2 ITH and predicting prognosis, including progression-free survival (PFS) and overall survival (OS), in patients with HER2-positive breast cancer [14]. The gene discussed is ERBB2; the disease is breast carcinoma.